Incyte : Retifanlimab Plus Chemotherapy Meets Primary Endpoint In Phase 3 SCAC Trial
13/6 04:34
(RTTNews) - Incyte Corp. (INCY) announced that primary results from the Phase 3 POD1UM-303/InterAACT 2 trial of retifanlimab (Zynyz)—a humanized monoclonal antibody targeting PD-1—combined with carboplatin and paclitaxel, have been published in The Lancet. The study focused on ad...